Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces clinically significant reductions in HbA1c and body weight in patients with type 2 diabetes, with efficacy superior to the selective GLP-1RA dulaglutide.
For patients with type 2 diabetes, tirzepatide offers superior glucose and weight control compared to existing GLP-1 drugs. To minimize stomach upset, it is crucial to follow the prescribed slow dose-escalation schedule (starting at 2.5mg or 4mg and increasing gradually over 8 weeks). This approach balances high efficacy with better tolerability.
HbA1c and body weight reductions by tirzepatide treatment (5 through 15 mg) were superior to those of dulaglutide.
Why this rating
Randomized, double-blind, placebo-controlled phase 2 trial with 111 participants.
Source
Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
Juan P. Frías et al. · Diabetes Obesity and Metabolism · 2020
DOI 10.1111/dom.13979
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →